[go: up one dir, main page]

AR032626A1 - Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas - Google Patents

Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas

Info

Publication number
AR032626A1
AR032626A1 ARP010103437A ARP010103437A AR032626A1 AR 032626 A1 AR032626 A1 AR 032626A1 AR P010103437 A ARP010103437 A AR P010103437A AR P010103437 A ARP010103437 A AR P010103437A AR 032626 A1 AR032626 A1 AR 032626A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
atom
preparation
amidas
ring
Prior art date
Application number
ARP010103437A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR032626A1 publication Critical patent/AR032626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Amidas seleccionadas a partir del grupo formado por compuestos de formula (1) en donde: R1 y R2 son independientemente hidrogeno, halo, ciano, nitro, alquiltio inferior, perfluor-alquiltio inferior, alquilsulfonilo inferior, o perfluor-alquilsulfonilo inferior; R3 es alquilo inferior C2-4 o un anillo de 5-7 miembros el cual es cicloalquilo, cicloalquenilo, o heterocicloalquilo con un heteroátomo seleccionado entre oxígeno y azufre; R4 es -C(O)NHR5, o es R6; R5 es hidrogeno, alquilo inferior, alquenilo inferior, hidroxi alquilo inferior, halo alquilo inferior, -(CH2)n-C(O)-OR7, o -C(O)-(CH2)n-C(O)-OR8; R6 es un anillo heteroaromático no sustituido o monosustituido de 5-6 miembros conectado por un átomo de C del anillo al grupo amida mostrado, conteniendo dicho anillo heteroaromático de 5-6 miembros 1-3 heteroátomos seleccionados a partir de azufre, oxígeno o nitrogeno, siendo un heteroátomo nitrogeno que es adyacente al átomo de C de conexion al anillo; dicho anillo heteroaromático mono-sustituido está mono-sustituido en una posicion en un átomo de C del anillo diferente del adyacente a dicho átomo de C de conexion con un sustituyente seleccionado a partir del grupo formado por alquilo inferior, halo, nitro, ciano, -(CH2)n-OR9, -(CH2)n-C(O)-OR10, -(CH2)n-C(O)-NH-R11, -C(O)-C(O)-OR12, o -(CH2)n-NHR13; n es 0, 1, 2, 3 o 4; R7, R8, R9, R10, R11, R12 y R13 son independientemente hidrogeno o alquilo inferior; X es oxígeno, azufre, sulfonilo o carbonilo; * indica un átomo de C asimétrico; y sus sales farmacéuticamente aceptables. Dichas amidas activan la glucoquinasa y por lo tanto son utiles en el tratamiento o profilaxis de la diabetes de tipo II. También se dan a conocer: composiciones farmacéuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas.
ARP010103437A 2000-07-20 2001-07-18 Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas AR032626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21987200P 2000-07-20 2000-07-20

Publications (1)

Publication Number Publication Date
AR032626A1 true AR032626A1 (es) 2003-11-19

Family

ID=22821104

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103437A AR032626A1 (es) 2000-07-20 2001-07-18 Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas

Country Status (21)

Country Link
US (2) US6486184B2 (es)
EP (1) EP1305301B1 (es)
JP (1) JP4138478B2 (es)
KR (1) KR100556323B1 (es)
CN (1) CN1184214C (es)
AR (1) AR032626A1 (es)
AT (1) ATE297907T1 (es)
AU (2) AU2001287600B2 (es)
BR (1) BR0112658A (es)
CA (1) CA2416229C (es)
DE (1) DE60111534T2 (es)
DK (1) DK1305301T3 (es)
ES (1) ES2243547T3 (es)
GT (1) GT200100146A (es)
MX (1) MXPA03000365A (es)
PA (1) PA8522701A1 (es)
PE (1) PE20020335A1 (es)
PT (1) PT1305301E (es)
UY (1) UY26850A1 (es)
WO (1) WO2002008209A1 (es)
ZA (1) ZA200300173B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
EP1458382A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
DE60309856T2 (de) 2002-04-26 2007-06-14 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1549626A1 (en) * 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CA2539596A1 (en) 2003-09-30 2005-04-07 Kilian Waldemar Conde-Frieboes Melanocortin receptor agonists
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
AU2005203930C1 (en) 2004-01-06 2012-02-23 Vtv Therapeutics Llc Heteroaryl-ureas and their use as glucokinase activators
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
RU2006138426A (ru) 2004-04-02 2008-05-10 Новартис АГ (CH) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
JP2007533722A (ja) * 2004-04-21 2007-11-22 プロシディオン・リミテッド トリ（シクロ）置換アミド化合物
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
JP2008509898A (ja) * 2004-08-12 2008-04-03 プロシディオン・リミテッド 置換されたフェニルアセトアミドおよびグルコキナーゼ活性化剤としてのこれらの使用
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
BRPI0613591A2 (pt) * 2005-07-08 2011-01-18 Novo Nordisk As ativadores de dicicloalquil uréia glicocinase
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
JPWO2007026761A1 (ja) 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
AU2006310474A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US7863329B2 (en) 2005-11-17 2011-01-04 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8138185B2 (en) 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
EP2125735B1 (en) 2007-02-28 2012-06-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
AU2008225613B2 (en) * 2007-03-07 2012-06-14 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
EP2236498A4 (en) 2008-01-18 2012-02-22 Astellas Pharma Inc PHENYLACETAMIDE DERIVATIVE
US8946440B2 (en) 2008-04-28 2015-02-03 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
PE20091901A1 (es) 2008-05-16 2010-01-06 Takeda San Diego Inc Activadores de glucoquinasa
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
CA2768232A1 (en) 2009-07-31 2011-02-03 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (gk) activators
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011095997A1 (en) 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Benzamide compounds as glucokinase activators and their pharmaceutical application
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP3199623B1 (en) 2010-03-31 2021-07-28 The Scripps Research Institute Reprogramming cells
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
JPS5564592A (en) * 1978-11-10 1980-05-15 Teijin Ltd Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it
JPS62153273A (ja) * 1985-12-26 1987-07-08 Tokuyama Soda Co Ltd ピラゾ−ル化合物
DK1169312T3 (da) * 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer

Also Published As

Publication number Publication date
US20020198200A1 (en) 2002-12-26
GT200100146A (es) 2002-07-04
CN1184214C (zh) 2005-01-12
CA2416229C (en) 2007-09-18
EP1305301A1 (en) 2003-05-02
KR100556323B1 (ko) 2006-03-03
CA2416229A1 (en) 2002-01-31
PE20020335A1 (es) 2002-04-30
DK1305301T3 (da) 2005-10-17
PA8522701A1 (es) 2002-10-24
JP2004504388A (ja) 2004-02-12
AU2001287600B2 (en) 2006-07-13
AU8760001A (en) 2002-02-05
WO2002008209A1 (en) 2002-01-31
BR0112658A (pt) 2003-06-24
EP1305301B1 (en) 2005-06-15
DE60111534D1 (de) 2005-07-21
KR20030016419A (ko) 2003-02-26
DE60111534T2 (de) 2006-05-11
US6608218B2 (en) 2003-08-19
ATE297907T1 (de) 2005-07-15
JP4138478B2 (ja) 2008-08-27
PT1305301E (pt) 2005-09-30
CN1443177A (zh) 2003-09-17
UY26850A1 (es) 2002-01-31
ZA200300173B (en) 2004-04-07
ES2243547T3 (es) 2005-12-01
US20020042512A1 (en) 2002-04-11
US6486184B2 (en) 2002-11-26
MXPA03000365A (es) 2003-05-27

Similar Documents

Publication Publication Date Title
AR032626A1 (es) Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas
AR031066A1 (es) Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
AR032752A1 (es) Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
UY28132A1 (es) Derivados de pirrolopirimidina
AR035639A1 (es) Derivados de para-aril o heterociclil sustituidos activadores de fenilglucoquinasa, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de medicamentos.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR035516A1 (es) Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR041009A1 (es) Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
AR032621A1 (es) Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos
AR019789A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
ES2175901T3 (es) Benzoimidazoles como inhibidores de la cilooxigenasa-2.
AR017177A1 (es) Compuesto derivados de 9-amino-3-ceto eritromicina, composiciones farmaceuticas, uso para la preparacion de un medicamento y procedimientos de preparacion.

Legal Events

Date Code Title Description
FG Grant, registration